A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial
MetadataDangos cofnod eitem llawn
Background Ethnicity, along with a variety of genetic and environmental factors, is thought to influence the efficacy of antihypertensive therapies. Current UK guidelines use a “black versus white” approach; in doing so, they ignore the United Kingdom's largest ethnic minority: Asians from South Asia. Study design The primary purpose of the AIM-HY INFORM trial is to identify potential differences in response to antihypertensive drugs used as mono- or dual therapy on the basis of self-defined ethnicity. A multicenter, prospective, open-label, randomized study with 2 parallel, independent trial arms (mono- and dual therapy), AIM-HY INFORM plans to enroll a total of 1,320 patients from across the United Kingdom. Those receiving monotherapy (n = 660) will enter a 3-treatment (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od), 3-period crossover, lasting 24 weeks, whereas those receiving dual therapy (n = 660) will enter a 4-treatment (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od), 4-period crossover, lasting 32 weeks. Equal numbers of 3 ethnic groups (white, black/black British, and Asian/Asian British) will ultimately be recruited to each of the trial arms (ie, 220 participants per ethnic group per arm). Seated, automated, unattended, office, systolic blood pressure measured 8 weeks after each treatment period begins will serve as the primary outcome measure. Conclusion AIM-HY INFORM is a prospective, open-label, randomized trial which aims to evaluate first- and second-line antihypertensive therapies for multiethnic populations.
American Heart Journal;
Mukhtar, O., Cheriyan, J., Cockcroft, J.R., Collier, D., Coulson, J.M., Dasgupta, I., Faconti, L., Glover, M., Heagerty, A.M., Khong, T.K., Lip, G.Y., Mander, A.P., Marchong, M.N., Martin, U., McDonnell, B. et al (2018) 'A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono-or dual therapy) on the basis of ethnicity: The comparIson of Optimal Hypertension Regimens; part of the Ancestry Informative Markers in Hypertension program—AIM-HY INFORM trial', American Heart Journal, 204, pp.102-108.
Dynodwr Gwrthrych Digidol (DOI)https://doi.org/10.1016/j.ahj.2018.05.006
Article published in American Heart Journal, available open access at https://doi.org/10.1016/j.ahj.2018.05.006
Cardiff Metropolitan University (Grant ID: Cardiff Metropolian (Internal))
Yn dangos eitemau sy’n perthyn drwy deitl, awdur, pwnc a chrynodeb.
Supporting carers to manage pain medication in cancer patients at the end of life: A feasibility trial Latter, Sue; Hopkinson, Jane; Lowson, Elizabeth; Hughes, Jane; Hughes, Jacqueline; Duke, Sue; Anstey, Sally; Bennett, Michael; May, Carl; Smith, Peter; Richardson, Alison (Sage, 2017-07-05)Background: Carers of people with advanced cancer play a significant role in managing pain medication, yet they report insufficient information and support to do so confidently and competently. There is limited research ...
Mughal, Durre (Cardiff Metropolitan University, 2015)This 9100 word creative portfolio with an accompanying 5781 word critical reflection explores the themes of mental health and ‘writing therapy’. Melancholia is about a girl in her early twenties who suffers from anxiety ...
Parr, Emily Louise (Cardiff Metropolitan University, 2012)Background: Asthma is reported to affect an estimated five million people in the UK. High incidence rates put the National Health Service under huge economic burden to provide treatment and medical care. Evidence suggests ...